Eucrates Biomedical Acquisition Corp. Unit
EUCRU
EUCRU was delisted on the 26th of April, 2023.
23 hedge funds and large institutions have $50.9M invested in Eucrates Biomedical Acquisition Corp. Unit in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 18 closing their positions.
38% less funds holding
Funds holding: 37 → 23 (-14)
44% less capital invested
Capital invested by funds: $90.4M → $50.9M (-$39.5M)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
78% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
+$4.24M |
| 2 |
HM
HealthCor Management
New York
|
+$3.56M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$216K |
| 4 |
Morgan Stanley
New York
|
+$41.5K |
| 5 |
CCM
Condor Capital Management
Martinsville,
New Jersey
|
+$27.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$9.86M |
| 2 |
6CM
683 Capital Management
New York
|
-$6.4M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$3.78M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$3.2M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$3.2M |
EUCRU Hedge Fund Activity: Q1 2021 in Review
23 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Unit (EUCRU) for Q1 2021, worth a combined $50.9M — down 44% from $90.4M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of EUCRU and 4 opened new positions — a net loss of 14 holders — while 6 trimmed existing stakes and 2 added.
The largest buyer was Verition Fund Management, opening a new position worth an estimated $4.24M. The largest seller was BlackRock, exiting entirely with an estimated $9.86M sold.
- 23 institutional investors held Eucrates Biomedical Acquisition Corp. Unit (EUCRU) as of Q1 2021, down from 37 in Q4 2020.
- Funds reported $50.9M of Eucrates Biomedical Acquisition Corp. Unit stock for Q1 2021, down 44% quarter-over-quarter.
- 4 funds opened new Eucrates Biomedical Acquisition Corp. Unit positions in Q1 2021 and 18 closed out, a net change of -14 holders.
- The largest Eucrates Biomedical Acquisition Corp. Unit buyer in Q1 2021 was Verition Fund Management, an estimated $4.24M added.
- The largest Eucrates Biomedical Acquisition Corp. Unit seller in Q1 2021 was BlackRock, an estimated $9.86M sold.
Based on aggregated 13F filings for Q1 2021.